# Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

> **NCT02930954** · PHASE2 · UNKNOWN · sponsor: **Caicun Zhou** · enrollment: 180 (estimated)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** pemetrexed or gemcitabine plus carboplatin,
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT02930954
- **Lead sponsor:** Caicun Zhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930954, "Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02930954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*